Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus lenalidomide vs rituximab in untreated follicular lymphoma
2010-021253-39Phase 2Active
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in follicular lymphoma (FL) comparing Rituximab plus lenalidomide with Rituximab monotherapy (2 arms). Primary endpoint: Complete response at week 23. Started Feb 2011; status: active.
02
Drugs
rituximablenalidomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2010-021253-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021253-39.